Published in JAMA · View the paper (DOI)
Losmapimod, a p38 MAPK inhibitor, failed to show cardiovascular benefits in patients hospitalized with acute MI. The trial found no reduction in recurrent major adverse cardiovascular events or all-cause mortality among patients treated with losmapimod compared to placebo.
Coverage from 2 institutions